Lesson plan

Drisapersen

Drisapersen (also known as Kyndrisa, PRO051 and GSK2402968 ) is an experimental drug that was under development by BioMarin, after acquisition of Prosensa, for the treatment of Duchenne muscular dystrophy. Drisapersen alters the splicing of the dystrophin RNA transcript, eliminating exon 51 from the mature dystrophin mRNA. Drisapersen is an antisense oligonucleotide (with the sequence 5'-UCA AGG AAG AUG GCA UUU CU-3') featuring a 2-O-methylribose sugar modification and phosphorothioate linkages.

Back to article

Article summary

Drisapersen (also known as Kyndrisa, PRO051 and GSK2402968 ) is an experimental drug that was under development by BioMarin, after acquisition of Prosensa, for the treatment of Duchenne muscular dystrophy. Drisapersen alters the splicing of the dystrophin RNA transcript, eliminating exon 51 from the mature dystrophin mRNA. Drisapersen is an antisense oligonucleotide (with the sequence 5'-UCA AGG AAG AUG GCA UUU CU-3') featuring a 2-O-methylribose sugar modification and phosphorothioate linkages.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.